<DOC>
	<DOCNO>NCT01953354</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness trichuris suis ovum ( TSO ) ulcerative colitis ( UC ) . We look TSO affect body 's immune response relate change participant ' UC .</brief_summary>
	<brief_title>Trichuris Suis Ova Treatment Left-sided Ulcerative Colitis</brief_title>
	<detailed_description>The cause UC , inflammatory bowel disease ( IBD ) , well understood . It believe cause abnormal immune response normal bacteria live gut ( intestines colon ) . This response act `` attack '' healthy tissue bowel person 's immune cell lead disease . It well know autoimmune disease IBD , asthma , diabetes , multiple sclerosis common industrialize , well-developed country well sanitation hygiene , United States . These `` cleaner '' environment reduce exposure germ parasites naturally find environment . This reduced exposure may trigger response body make people prone diseases UC . People non-industrialized country tropic , parasite common , rarely develop disease . This observation lead researcher want good understand relationship lack natural bacteria gut onset autoimmune disease like UC .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>1 . Subject provide write informed consent 2 . Diagnosis UC ( newly diagnose establish patient ) determine medical history , endoscopic histological confirmation proximal disease extent limit leave colon ( distal splenic flexure ) , accessible flexible sigmoidoscopy . Patients leftsided disease presence periappendiceal red patch ( limited cecal inflammation ) eligible long intervening evidence colitis cecal base upper boundary inflammation leave colon . 3 . Mayo score &gt; /= 4 , score Screen 2 4 . If take follow medication Screen 1 , subject must meet following criterion : 1 . Oral Corticosteroids : stable treatment least 4 week prior Day 0 maximum dose equivalent &lt; \=15 mg/day prednisone 2 . Immunosuppressants ( azathioprine ( AZA ) 6mercaptopurine ( 6MP ) ) : treatment least 12 week stable dose , exceed 2.5 mg/kg/day AZA 1.5 mg/kg/day 6MP , 4 week prior Day 0 3 . Aminosalicylates : stable oral dos 4.8 g/day least 4 week prior Day 0 . 1 . Subjects whose UC anticipate require surgical , endoscopic , radiologic intervention study participation 2 . Uncontrolled GI bleed 3 . Subjects disease limit rectum ( maximum disease extent le 15 cm ) 4 . Women pregnant , breastfeeding , plan become pregnant study . All woman childbearing potential must negative serum pregnancy test Screen 2 prior randomization treatment . 5 . Women childbearing potential use adequate birth control measure ( e.g. , total abstinence , oral contraceptive , intrauterine device , barrier method spermicide , surgical sterilization , DepoProvera , hormonal implant ) . 6 . Current recent serious systemic disorder include clinically significant impairment cardiac , pulmonary , liver , renal , endocrine , hematologic , neurologic function , base investigator discretion 7 . Subjects currently receive follow concomitant medication : 1 . Prednisone equivalent unstable dos dose exceed 15 mg/day within 4 week prior Day 0 2 . Local steroid budesonide , Colifoam , Predsol enemas within 2 week prior Screen 2 3 . Topical therapy , either mesalamine steroid , take within 2 week Screen 2 4 . Nonsteroidal antiinflammatory drug ( NSAIDs ) , Cyclooxygenase ( COX ) 2 inhibitor , aspirin &gt; 100 mg/day within 2 week prior Screen 2 5 . Tumor necrosis factor ( TNF ) alpha inhibitor include limited infliximab ( Remicade ) adalimumab ( Humira ) within 12 week Day 0 6 . Any biological agent within 12 week Day 0 7 . Metronidazole within 4 week Day 0 8 . Receipt investigational agent within 12 week prior Day 0 9 . Antibacterial oral antifungal agent within 4 week Screen 2 10 . Interferon ( IFN ) therapy 11 . Anticoagulants 12 . Methotrexate 8 . Blood transfusion within 12 week prior Day 0 9 . Presence follow abnormal laboratory parameter Screen 1 : 1 . Hemoglobin &lt; 10.0 g/dL 2 . White Blood Count ( WBC ) &lt; 4,000 &gt; 20,000/L ( equivalent WBC &lt; 4 &gt; 20 x109/L ) 3 . Platelets &lt; 100,000 &gt; 800,000/L ( equivalent platelet &lt; 100 &gt; 800 x109/L ) 4 . Total bilirubin &gt; 1.5 × Upper limit normal ( ULN ) 5 . Alanine transaminase ( ALT ) &gt; 2 × ULN 6 . Aspartate transaminase ( AST ) &gt; 2 × ULN 7 . Alkaline phosphatase ( ALK ) &gt; 1.5 × ULN 8 . Gammaglutamyl transferase ( GGT ) &gt; 1.5 × ULN 9 . Creatinine &gt; 1.5 × ULN 10 . History drug alcohol abuse within one year prior Day 0 11 . Inability understand nature requirement study , comply study procedure plan schedule study visit 12 . Evidence infection human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C 13 . Active infection C. difficile , bacterial enteric pathogen , pathogenic ova/parasites 14 . History malignancy within last 5 year , except resect basal squamous cell carcinoma , treat cervical dysplasia , treat situ cervical cancer Grade I 15 . History colonic dysplasia 16 . Any social medical condition , opinion investigator , would preclude provision inform consent , make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ulcerative colitis ( UC )</keyword>
	<keyword>Inflammatory Bowel Disease ( IBD )</keyword>
	<keyword>Trichuris suis ovum ( TSO )</keyword>
</DOC>